Back to Archived Journals » Oncolytic Virotherapy » Volume 4 » default

Oncolytic Virotherapy ceased publishing in January 2023. All articles that have been published in Oncolytic Virotherapy will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.

Oncolytic Virotherapy

ISSN: 2253-1572


       

Archive: Volume 4, 2015

Oncolytic virotherapy using herpes simplex virus: how far have we come?

Sokolowski NAS, Rizos H, Diefenbach RJ

Oncolytic Virotherapy 2015, 4:207-219

Published Date: 25 November 2015

Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art

Nande R, Howard CM, Claudio PP

Oncolytic Virotherapy 2015, 4:193-205

Published Date: 25 November 2015

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy

Nakashima H, Nguyen T, Chiocca EA

Oncolytic Virotherapy 2015, 4:183-191

Published Date: 20 November 2015

Targeting tumor vasculature through oncolytic virotherapy: recent advances

Toro Bejarano M, Merchan JR

Oncolytic Virotherapy 2015, 4:169-181

Published Date: 11 November 2015

Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology

Ramírez M, García-Castro J, Melen GJ, González-Murillo A, Franco-Luzón L

Oncolytic Virotherapy 2015, 4:149-155

Published Date: 14 October 2015

Oncolytic Sendai virus-based virotherapy for cancer: recent advances

Saga K, Kaneda Y

Oncolytic Virotherapy 2015, 4:141-147

Published Date: 1 October 2015

Oncolytic virotherapy for human malignant mesothelioma: recent advances

Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, Fonteneau JF

Oncolytic Virotherapy 2015, 4:133-140

Published Date: 10 September 2015

Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor

Sakr HI, Coleman DT, Cardelli JA, Mathis JM

Oncolytic Virotherapy 2015, 4:119-132

Published Date: 4 September 2015

Advances in the design and development of oncolytic measles viruses

Hutzen B, Raffel C, Studebaker AW

Oncolytic Virotherapy 2015, 4:109-118

Published Date: 27 August 2015

Oncolytic virotherapy for head and neck cancer: current research and future developments

Malhotra A, Sendilnathan A, Old MO, Wise-Draper TM

Oncolytic Virotherapy 2015, 4:83-93

Published Date: 20 July 2015

Promising oncolytic agents for metastatic breast cancer treatment

Cody JJ, Hurst DR

Oncolytic Virotherapy 2015, 4:63-73

Published Date: 3 June 2015

Therapeutic potential of oncolytic Newcastle disease virus a critical review

Tayeb S, Zakay-Rones Z, Panet A

Oncolytic Virotherapy 2015, 4:49-62

Published Date: 27 March 2015

Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy

Whisenhunt Jr TR, Rajneesh KF, Hackney JR, Markert JM

Oncolytic Virotherapy 2015, 4:33-38

Published Date: 30 January 2015

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)

Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J

Oncolytic Virotherapy 2015, 4:25-31

Published Date: 28 January 2015